Glenmark FabiFlu Public Reviews n Complaints


Drug major Glenmark Pharma is the first Indian company to commercially launch an antiviral drug – Favipiravir with brand name FabiFlu – for the treatment of mild to moderate COVID-19 patients. The company received marketing and manufacturing approval from the Indian drug regulator, Drug Controller General of India (DCGI) and launched the product in the Indian market today.

The Priced of FabiFlu Rs 3,500 for a pack of 34 tablets (Rs 103 per tablet), the dosage is 200 mg X 9 tablets on the day one and 200 mg X 4 tablets a day for 14 days of the treatment. Glenmark did a clinical trial among 90 mild and 60 moderate COVID-19 patients across 11 sites in India. The drug is claimed to have an efficacy of over 80% in the treatment of COVID-19 mild to moderate patients.


So now please share your experience with this antiviral drug…

Please Comment below your Experience or complaint about his drug


Leave a Comment